Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development

By: via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.